The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

$ 25.99
  • By A Mystery Man Writer
  • 4.8(474)
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Product Description

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

What sustains the multidrug resistance phenotype beyond ABC efflux

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Protein degradation: expanding the toolbox to restrain cancer drug

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Targeted Protein Degradation for Infectious Diseases: from Basic

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Protein degradation: expanding the toolbox to restrain cancer drug

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Amanda Purdy on LinkedIn: The drug efflux pump MDR1 promotes

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Antibodies, Free Full-Text

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

IJMS, Free Full-Text

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Lapatinib May Boost Effectiveness of Drugs That Destroy Cancer

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Crizotinib‐based proteolysis targeting chimera suppresses gastric

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Cancers, Free Full-Text

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to  PROTACs in cancer cells

Protein degradation: expanding the toolbox to restrain cancer drug